Heparin neutralisation by recombinant platelet factor 4 and heparinase

Published

Journal Article (Review)

Our clinical armamentarium requires alternatives to protamine. Initial human data with rPF4 reveal an effective safe agent. The adverse haemodynamic effects in lambs may derive from species variability, or may represent a cause for concern. Data from human studies must be collected, especially during cardiac surgery. Currently, rPF4 appears to represent an important alternative to protamine for the reversal of heparin anticoagulation. Heparinase effectively and safely neutralises heparin anticoagulation in animal models. Additional human data will determine its applicability to clinical medicine.

Duke Authors

Cited Authors

  • Levy, JH; Michelsen, LG

Published Date

  • January 1, 1995

Published In

Volume / Issue

  • 3 / 2

Start / End Page

  • 112 - 117

International Standard Serial Number (ISSN)

  • 0966-7954

Citation Source

  • Scopus